[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pontine-tumors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pontine-tumors":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100523249",false,"NCT06093165","RE-irradiation of Diffuse MIdline Glioma paTients","REMIT","Inclusion Criteria:\n\n* Diffuse midline glioma diagnosis: verified radiologically or histologically Biopsy is not mandatory for REMIT\n* Age ≥ 12 months to ≤21 years.\n* Min. 180 days\u002F6 months have elapsed from the first day of the 1st RT course\n* 1st course of radiotherapy\n* Full recovery from all acute and subacute toxicities of 1st RT course\n* Clinical progression of symptoms and\u002For radiographic progression\n* Karnofsky performance status scale or Lansky Play Scale \\> 50% The performance status should not take the neurological deficits per se into account.\n\nNB: Children and adults with a worsening performance status due to glioma-related motor deficit can be included.\n\n* Life expectancy \\> 12 weeks after start of reRT\n* Signed informed consent by patient and\u002For parents or legal guardian\n\nExclusion Criteria:\n\n* Presence of leptomeningeal spread or multifocal disease on MRI at progression\n* Other co-morbidity that according to the treating physician would impair participation in the study\n* \\>1 course of radiotherapy\n* Neurofibromatosis type 1\n* Inability to complete the medical follow-up (geographic, social, or mental reasons)","ALL","12 Months","21 Years",{"count":19,"type":20},59,"ESTIMATED","INTERVENTIONAL",[23],"NA","The REMIT (RE-irradiation of diffuse MIdline glioma paTients) study evaluates safety and the palliative efficacy of re-irradiation of patients with diffuse midline glioma (DMG). The study will introduce a standard re-irradiation treatment schedule for DMG patients who have progressed following primary treatment.",[26,27,28,29,30,31],"Diffuse Midline Glioma, H3 K27M-Mutant","Diffuse Intrinsic Pontine Glioma","Diffuse Glioma","Pontine Tumors","Thalamic Tumor","Brain Tumor, Pediatric","NOT_YET_RECRUITING","2023-10-16",{"date":35,"type":36},"2023-10-23","ACTUAL",{"date":38,"type":20},"2023-10",{"date":40,"type":20},"2029-11",{"name":42,"class":43},"Rigshospitalet, Denmark","OTHER",""]